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Abstract: Objective: To evaluate predictors of severity and duration of early Multiple Sclerosis (MS) attacks. 
Methods: We analyzed 248 attacks in 95 patients in a prospective study. Severity: the difference between the EDSS score 
at the day of maximum worsening and the EDSS score before the onset of the attack. Duration: the time between the date 
of onset of the first symptom and the date of maximum improvement of the last symptom. 
Results: The number of involved Functional Systems (FS), FS type (brainstem and pyramidal), and total attack duration 
were linked to severity. Number of FS involved, FS type (sphincteric and sensory), and severity of the attack were related 
to duration. Neither severity nor duration were correlated to other predictors: gender, age and season at attack onset, speed 
of onset, infections in the preceding month, age at first attack, season of birth and first attack, CSF examination, first brain 
MRI, recovery from the first attack. In the multivariate analysis, the Odds Ratio (OR) and Confidence Intervals (CI) for 
severe attacks was 3.6, 1.7-7.7 for involvement of pyramidal FS, 2.6, 1.2-6.0 for brainstem and 2.5, 1.2-5.3 for long attack 
duration. Sphincteric (4.4; 1.7-11.0) and sensory FS (1.8; 1.0-3.2) were the only variables explaining duration. The prob-
ability of a second moderate/severe or long attack was not influenced by severity or duration of the first. 
Conclusions: FS are predictive of severity and duration of early MS attacks. Severity and duration of the first attack do not 
predict severity and duration of the second.  
Keywords: Course, Duration, Multiple sclerosis, Prognosis, Recovery, Attack, Relapse, Severity. 
INTRODUCTION 
Clinical features of attacks in multiple sclerosis (MS) 
widely differ among patients and recovery is incomplete in 
one-third [1-3]. Incomplete recovery, indeed, is a strong pre-
dictor of a poor prognosis [4-7]. Severity has consistently 
been identified as the most powerful predictor of incomplete 
recovery, together with age and polysymptomatic onset [1, 2, 
4, 8]. However, factors that determine attack severity have 
been assessed in only one study [4] that identified younger 
age and brainstem/cerebellar location as predictors of sever-
ity, and showed that the severity of the first attack predicted 
that of the second. Factors that determine duration have 
never been evaluated. We have conducted an exploratory 
prospective study to look for factors that predict severity and 
duration of early attacks in patients with clinically isolated 
syndrome (CIS) and relapsing-remitting (RR) MS. We as-
sumed that factors related to the characteristics of each attack 
(age and season at attack onset, previous infections, type, 
number, and speed of onset of symptoms, attack therapy) or 
to the characteristics of the patient or disease   
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course (gender, age at first attack of MS, season of birth and 
first attack, CSF and MRI features) influence severity and 
duration of MS attacks. In addition, we evaluated whether 
the severity and duration of and the recovery from the first 
MS attack are associated with the severity and duration of 
the second. 
MATERIALS AND METHODOLOGY 
Patients and Follow-Up 
We enrolled 95 consecutive patients admitted to the No-
vara and Cuneo MS Centers from January 2001 (Cuneo from 
May 2002) to December 2003. Both centers are first-referral 
facilities which a total catchment area of 600,000 persons. 
We included patients presenting with CIS or RR-MS. CIS 
was defined as the occurrence of an acute or subacute event 
of the CNS affecting the optic nerves, brainstem or spinal 
cord of presumed inflammatory demyelinating origin in a 
patient with no history suggestive of an earlier demyelinating 
episode [9]. McDonald criteria [10] were used to diagnose 
MS. Primary progressive MS patients were excluded.  
The cohort comprised 51 women and 44 men with a 
mean ages of 35.4 years (SD 10.6) and 31.4 (9.2) (p<0.05) at 
the first attack. The median interval between first symptom 
and visit was 51 days, (range 0-810). Patients were enrolled 76     The Open Neurology Journal, 2011, Volume 5  Naldi et al. 
on their first visit to one of the two Centers. This corre-
sponded to the first attack in 55 cases (58%). The others 
were observed 1 to 27 months after the first attack (only 13 
during or after the second). All patients had MRI; cerebro-
spinal fluid (CSF) was examined in 79. Other examinations 
were performed to rule out an alternative diagnosis. After the 
first visit, patients were clinically evaluated every 6 months 
until the end of the follow-up (July 31, 2005). During each 
visit, they were scored according to the Expanded Disability 
Status Scale (EDSS) [11]. Follow-up ranged from 19 to 55 
months (mean 36.8; SD 10.2). At the end of follow-up, 21 
were still CIS and 71 RR-MS; 3 patients had already entered 
secondary progression. For patients who presented a relapse 
in the last semester of the follow-up, an extra 12-month pe-
riod (after July 31) was added to ascertain recovery (not con-
sidered in calculation of the mean follow-up).  
Patients were instructed to phone the MS Center on the 
appearance of new symptoms and a visit was arranged in no 
more than 3 days. Further visits were planned after 3 and 5 
days, and 1 month after the attack onset. Each attack was 
evaluated by an examiner neurologist blind to the treating 
neurologist. Each patient was provided at the beginning of 
the attack with a diary, derived from Liu [12] and asked to 
indicate each symptom and circle each day in which it was 
present. Diaries were collected at the end of the attack, and 
their information was integrated with that from the inter-
view. Data on attacks not directly observed by us (anamnes-
tic attacks, N=77, 40 first) were collected from hospital dis-
charge letters, emergency departments and outpatient neuro-
logical reports, and integrated through interviews of patients 
and their relatives. Decision whether or not to treat an attack 
(either orally or intravenously) was left to the patient’s phy-
sician. Seventeen patients were started on disease-modifying 
therapy (15 interferon, 2 glatiramer acetate) during the fol-
low-up period, only in two cases before the second attack. 
The study was approved by the Ethical Committee of our 
Hospital; written informed consent was obtained to partici-
pate in the study and maintain data in the data-base. 
Attack Definition 
Attack was defined as “acute or subacute occurrence, re-
currence or worsening of symptoms of neurologic dysfunc-
tion attributable to MS, lasting more than 24 hours after a 
period of at least 30 days of improvement or stability” [13]. 
Neurological deterioration of pre-existing symptoms accom-
panied by fever or concomitant infection (pseudoexcerba-
tion) was not considered a attack. Paroxysmal episodes were 
considered as attacks when multiple and occurring over not 
less than 24 hours. Symptoms occurring within a month after 
the initial symptoms of an attack were considered to be part 
of the same episode [10]. For each attack, type of symptoms 
and signs and dates of occurrence were collected on an ad-
hoc form, derived from Trojano et al [14]. Symptoms and 
signs were grouped to fit in with the Kurtzke Functional Sys-
tems (FS) [11]. For each symptom/sign we defined the date 
of onset, maximum worsening (zenith), start of improve-
ment, and maximum improvement, defined as the date after 
which no further subjective improvement was noted. The 
score for each FS and the total EDSS score were calculated 
at onset, at the zenith and at the first examination after the 
day of maximum improvement. Agreement between the “at-
tack” examiners was calculated with the Kappa statistics and 
varied from 0.7 to 0.9 for each FS [1].  
Definition of Severity, Duration and Predictive Factors 
Severity was graded according to the difference between 
the EDSS score at the day of maximum worsening and the 
EDSS score before the onset of the attack, as: very mild (0 or 
1 point), mild (1.5 or 2 points), moderate (2.5 or 3 points), 
and severe (3.5 points or more). Duration was calculated as 
the time between the date of onset of the first symptom and 
the date of maximum improvement of the last symptom and 
classed as short (30 days), intermediate (31-60 days) and 
long (>60 days). We evaluated two groups of predictive fac-
tors related to either the single attack or the single patient, 
including disease course characteristics. Attack-related fac-
tors were: age at the onset of the attack, season of the attack, 
type of FS involved, speed of onset, number of affected FS, 
infections in the preceding month, and therapy of the attack. 
Patient-related factors were: gender, age at first attack, sea-
son of birth and of first attack, oligoclonal bands at CSF ex-
amination, Link Index, CSF IgG value, total number and 
number of gadolinium-enhancing lesions at first brain MRI. 
Recovery after the first attack was considered incomplete 
when the difference between the score at the date of maxi-
mum improvement and the score before the onset of the at-
tack was 1 for at least one FS [1]. The definition of the 
other predictive variables are reported in our previous paper 
[1]. 
Data were analyzed with SAS [15]. Statistical compari-
sons were performed with Student’s t test for independent 
samples, chi-square and chi-square for trend where appropri-
ate. Spearman’s coefficient was used for correlations. In 
view of the large number of comparisons, the Bonferroni 
correction for statistical significance was used. Odds Ratios 
(OR) with 95% confidence intervals (CI) were calculated. 
For multivariate analyses, possible predictors were dichoto-
mized as follows: monosymptomatic vs. bi-polysympto-
matic; severe vs. very mild+mild+moderate; long vs. inter-
mediate+short, attack therapy vs. no therapy, season 
spring+summer vs. autumn+winter, age at attack onset < 30 
vs. >=30. A multiple logistic regression was performed using 
SAS/LOGISTIC [15], with duration and severity as the de-
pendent variable, entering the predictor variables significant 
after univariate analysis and attack therapy (forward stepwise 
selection model with significance level for retention at 0.05).  
In another statistical approach, we calculated the cumula-
tive time-dependent probability of a second moderate/severe 
or long attack by the Kaplan-Meier method with 95% confi-
dence intervals (CI). Date of entry was the date of onset of 
the first attack and the date of end-point was the date of on-
set of a severe/moderate or long attack, or July 31, 2005, 
whichever came first. Patients having a second non-
moderate/severe or non-long attack were censored at the 
time of their second attack. Categories of severity and dura-
tion were used as possible prognostic predictors of a attack. 
The log-rank test was used to test the significance of differ-
ences between groups. Multivariable Cox proportional haz-
ard modeling was used to control for potential predictors of 
the probability of relapsing (SAS/PHREG) [15]. Predictors 
were entered into the model simultaneously.  
 Severity and Duration of Multiple Sclerosis Attacks  The Open Neurology Journal, 2011, Volume 5    77 
RESULTS 
During the follow-up we counted 248 attacks (171 ob-
served and 77 anamnestic): 95 first, 62 second, 33 third, 22 
fourth, 16 fifth, and 20 subsequents. Very mild and mild 
attacks were more frequent (p<0.01) among the anamnestic 
(46/77, 60%) than the observed (69/171, 40%). Intravenous 
therapy was done for 26 anamnestic attacks (34%), com-
pared to 99 observed (58%, p<0.001). No significant differ-
ences were found between observed and anamnestic attacks 
in terms of frequency of all the other possible predictive fac-
tors; therefore anamnestic and observed attacks have been 
combined in the analysis.  
Table 1.  Severity of 248 MS Attacks, According to Attack-Related Characteristics 
Severity
a  
  very  mild  mild  moderate severe  
Predictive  Factor  N % N % N % N  %  p-value
b 
Number of FSs involved 
Monosymptomatic  52 34.9 60 40.3 29 19.5  8  5.4   
Bisymptomatic  9  15.8 18 31.6 19 33.3 11 19.3  <0.0001
c 
Polysymptomatic    4  9.5  11 26.2 11 26.2 16 38.1   
Type of FS involved 
d 
Pyramidal  yes  18 18.4 33 33.7 24 24.5 23 23.5  =0.003 
  no  47 31.3 56 37.3 35 23.3 12  8.0   
Cerebellar  yes    6 18.8 7 21.9 9 28.1  10  31.3  n.s 
  no  59 27.3 82 38.0 50 23.2 25 11.6   
Brainstem  yes  5  9.8  15 29.4 19 37.3 12 23.5  <0.001 
  no  60 30.5 74 37.6 40 20.3 23 11.7   
Visual  yes    16 23.2 28 40.6 13 18.8 12 17.4  n.s 
  no  49 27.4 67 34.1 46 25.7 23 12.9   
Sphincteric  yes    4 17.4 6 26.1 6 26.1 7 30.4  n.s 
  no    61 27.1 83 36.9 53 23.6 28 12.4   
Sensory  yes    32 24.8 44 34.1 30 23.3 23 17.8  n.s 
  no  33 27.7 45 37.8 29 24.4 12 10.1   
Total attack duration
e 
Short    21 25.3 38 45.8 18 21.7  6  7.2   
Intermediate  32 36.0 26 29.2 19 21.4 12 13.5  =0.003
c 
Long  12 15.8 25 32.9 22 29.0 17 22.4   
Therapy 
No  25 38.5 20 30.8 13 20.0  7  10.8   
Oral  20 34.5 24 41.4 12 20.7  2  3.5  =0.001 
Intravenous  20 16.0 45 36.0 34 27.2 26 20.8   
aSeverity was graded according to the difference between the EDSS score at the day of maximum worsening and the EDSS score before the onset of the relapse, as: very mild (0 or 1 
point), mild (1.5 or 2 points), moderate (2.5 or 3 points), and severe (3.5 points or more). 
bLevel of significance at 0.003 according to the Bonferroni correction. 
cDenotes the chi-square for trend test. 
dHere the type of FS (except mental and others) involved in each attack is cross-tabulated against grade of severity.  
eCalculated as the time between the date of onset of the first symptom and the date of maximum improvement of the last symptom and categorized as short ( 30 days), intermediate 
(31-60 days) and long (>60 days). 
The following factors were not statistically related to severity: age at onset of the attack (<30, 30-39, 40), season of onset of the attack, infections in the preceding month, speed of 
onset (calculated as the time between the date of onset and the date of zenith and categorized as acute if the same day, subacute if 2-3 days, and chronic >3 days), gender, age at first 
attack (<30, 30-39, 40), season of birth and of first attack, oligoclonal bands at CSF examination (present/absent), Link Index ( 0.70/>0.70) CSF IgG value ( 0.40/>0.40 mg/dl), 
total number of lesions (0,1-8, 9 lesions), and number of gadolinium-enhancing lesions at first brain MRI (0,1, >1 lesions), and recovery after the first relapse (com-
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Attack Severity 
65 attacks (26%) were very mild, 89 (36%) mild, 59 
(24%) moderate, and 35 (14%) severe. Table 1 shows the 
degree of severity according to the attack-related predictive 
factors. Pyramidal and brainstem FS, number of FS involved 
and total attack duration were related to severity, the last two 
with a clear trend. As expected, iv. therapy was most fre-
quent in more severe attacks. The highest risk of a severe 
attack was for pyramidal (OR 3.5, 95% CI 1.7-7.5) and cere-
bellar FS (3.5, 1.5-8.2), followed by sphincteric (3.1, 1.2-
8.1) and brainstem (2.3, 1.1-5.1). Sensory (1.9, 0.9-4.1) and 
visual (1.4, 0.7-3.1) FS did not significantly increase the risk 
of a severe attack. Attacks with visual symptoms were more 
frequently monosymptomatic (45/69, 65%) than those with 
sensory (50/129, 39%), brainstem (17/51, 33%), motor 
(31/98, 32%), cerebellar (5/32, 16%), and sphincteric symp-
toms (1/23, 4%). To avoid bias determined by the multiple 
inclusion of attacks from single patient, we correlated pa-
tient-related predictive factors to attack severity separately 
for the first and second attack: none of them was correlated 
with the degree of severity (data not shown). In the multi-
variate model, the number of symptoms (mono vs. bi-
polysymptomatic) was the only variable that explained se-
verity (OR for severe attacks: 6.6; 95% CI 2.9-15.3). Since 
the number of FS is highly related with severity due to the 
measurement procedure, we performed another analysis, 
without number of FS. The following variables were retained 
after stepwise selection: pyramidal (OR 3.6, 1.7-7.7), brain-
stem (2.6, 1.2-6.0), and long duration (2.5, 1.2-5.3). 
Attack Duration 
83 attacks (34%) were classed as short, 89 (36%) as in-
termediate, and 76 (31%) as long. Table 2 shows the dura-
tion according to the attack-related predictive factors. Num-
ber of FS, type of FS involved (sphincteric and sensory) and 
severity of the attack were related to duration. The risk of a 
long duration was significant only for sphincteric (5.0; 2.0-
12.5), and sensory (2.1, 1.2-3.6) FS involvement. None of 
patient-related predictive factors was correlated with the 
duration of both the first and second attack (data not shown). 
Table 2.  Duration of 248 MS Attacks, According to Attack-Related Characteristics 
Attack duration 
a 
  short intermediate  long  p-value 
Predictive  Factor  N % N % N %   
Number of FSs involved 
Monosymptomatic  59 39.6 53 35.6 37 24.8   
Bisymptomatic  17 29.8 25 43.9 15 26.3 <0.0005
c 
Polysymptomatic    7  16.7 11 26.2 24 57.1   
Type of FS involved 
d 
Pyramidal  yes  30 30.6 35 35.7 33 33.7  n.s. 
  no  53 35.3 54 36.0 43 28.7   
Cerebellar  yes    10 31.2  9  28.1 13 40.6  n.s. 
  no  73 33.8 80 37.0 63 29.2   
Brainstem  yes  18 35.3 19 37.3 14 27.5  n.s. 
  no  65 33.0 70 35.5 64 31.5   
Visual  yes    23 33.3 23 33.3 23 33.3  n.s. 
  no  60 33.5 66 36.9 53 29.6   
Sphincteric yes   2  8.7  6  26.1  15  65.2  <0.001 
  no    81 36.0 83 36.9 61 27.1   
Sensory  yes    31 24.0 49 38.0 49 38.0  =0.002 
  no    52 43.7 40 33.6 27 22.7     
Severity 
Very  mild  21 32.3 32 49.2 12 18.5   
Mild  38 42.7 26 29.2 25 28.1     
Moderate    18 30.5 19 32.2 22 37.3  =0.003
c 
Severe  6  17.1 12 34.3 17 48.6   
aCalculated as the time between the date of onset of the first symptom and the date of maximum improvement of the last symptom and categorized as short ( 30 days), intermediate 
(31-60 days) and long (>60 days). 
See Table 1 for the other definitions 
The following factors were not statistically related to duration: attack therapy, age and season of onset of the attack, infections in the preceding month, speed of onset, gender, age at 
first attack, season of birth and of first attack, oligoclonal bands at CSF examination, Link Index, CSF IgG, total number of lesions and number of gadolinium-enhancing lesions at 
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In the multivariate model, sphincteric (4.4, 1.7-11.0) and 
sensory symptoms (1.8, 1.0-3.2) were the only variables ex-
plaining duration. 
Probability of a Severe or Long Second Attack 
In a different approach, we tested whether the probability 
of a second severe or long attack was influenced by severity 
and duration of the first. Since the number of second severe 
attacks was small (N=7) we grouped them with moderate 
second attacks (N=13). The probability of a second moder-
ate/severe or long attack was not influenced by severity or 
duration of the first (Figs. 1 and 2). The 3-year probability of 
a second moderate/severe attack was 21% (4-38) for a pa-
tients with a severe first attack and 22% (12-32) for those 
with a very mild-mild-moderate first attack (p=0.71). It was 
23% (9-37) for a patients with a long first attack, and 21% 
(10-32) for those with a short-intermediate first attack 



































Fig. (1). Cumulative time-dependent probability of a second moderate/severe attack according to severity and duration of the first. The 3-
year probabilities were: 21% (4-38) for patients with a severe first attack, 17% (4-31) for moderate, 29% (12-46) for mild, and 17% (0-38) 
for very mild (p=0.70); 23% (9-37) for patients with a long first attack, 24% (7-41) for intermediate and 18% (5-32) for short (p=0.81). 80     The Open Neurology Journal, 2011, Volume 5  Naldi et al. 
23% (7-39) for a patients with a severe first attack, and 14% 
(6-23) for those with a very mild-mild-moderate first attack 
(p=0.22). It was 15% (5-24) for patients with a long first 
attack, and 20% (7-32) for those with a short-intermediate 
first attack (p=0.53). We performed a multivariate analysis, 
including all attack-related factors, gender and recovery after 
the first attack (Table 3); other factors not significant in the 
univariate analysis were not included. The only predictive 
(negative) variable for a moderate/severe second attack was 
incomplete recovery from the first attack.  
DISCUSSION 
In accordance with our previous study [1], we divided 
predictive factors into attack-related and patient-related. 
None of the patient-related features was predictive of attacks 
severity or duration. Among attack-related factors, the num-
ber of FS involved was the only predictor of severity after 
the multivariate analysis; since the grade of severity in our 
categorization was not independent from the number of af-
fected FS, we cannot draw any conclusion on the relation 


































Fig. (2). Cumulative time-dependent probability of a second long attack according to severity and duration of the first. The 3-year probabili-
ties were: 23% (7-39) for patients with a severe first attack, 15% (1-29) for moderate, 13% (0-26) for mild, and 17% (0-38) for very mild 
(p=0.61); 20% (7-33) for patients with a long first attack, 16% (2-31) for intermediate and 13% (1-26) for short (p=0.75). Severity and Duration of Multiple Sclerosis Attacks  The Open Neurology Journal, 2011, Volume 5    81 
verity. Severity clearly differed among FS, pyramidal and 
brainstem being the most severe both in the univariate and 
the multivariate analyses. Similar differences were found by 
Mowry et al., [4] in 330 patients. Whether this has biological 
plausibility (e.g. a different degree of inflammation in differ-
ent FS) or is a mere consequence of the score system is not 
clear. Score levels of each FS are not equivalent, and moving 
from one score to another might not have the same biological 
meaning for visual, sensory or pyramidal FS. The lower se-
verity of attacks with optic nerve involvement may also de-
pend on the fact that they were more frequent monosympto-
matic. Attack duration was one of the factors determining 
severity; a longer exposure to toxic substances [16] might 
determine more damage and lower possibility of recovery. 
Assessment of duration is hampered by uncertainly as to 
the exact moment when an attack ends. Despite the fact that 
no mean duration could be established since attack ends had 
to be estimated, our three categories clearly identify different 
durations. Severity and number of symptoms were predictive 
of long duration in the univariate analysis, but the multivari-
ate model retained only two individual FS, sphincteric and 
sensory. Attacks with sphincteric symptoms were almost 
always polysimptomatic and it is also likely that the end of 
such attacks cannot be readily evaluated. We couldn’t com-
pare these data, because factors predicting duration have 
never been investigated hitherto. 
Mowry et al., [4] claimed a substantially increased risk of 
a more severe subsequent event for those with poor recovery 
from the first, and a tendency to repeat the degree of severity 
in attacks subsequent to the first. We did not find any rela-
tion of severity or duration in the first attack to severity or 
duration in the second. However the grading systems were 
different and cannot be fully compared. Patients with incom-
plete recovery from the first attack had a lower probability to 
have a moderate/severe, but not a long second attack. This 
should be interpreted in the context of our measure proce-
dure: patients with a residual high score from the first attack 
were probably unable to reach a higher score for the second, 
especially if this occurred in the same FS. Thus attacks with 
equal severity scored higher and were deemed longer when 
the first recovered to EDSS 0. Evaluation of third and later 
attacks could help to understand this point better, but we had 
a too low number of such attacks to analyze.  
Some limitations of our study must be duly acknowl-
edged. Firstly, our analyses was confined to attacks during 
early stages of the natural history of MS, and our findings 
cannot be automatically transferred to later attacks. Sec-
ondly, steroid management was not standardized, and treat-
ment was left to the patient’s own physician. Patients with 
more severe attacks were treated more frequently with ster-
oids. Since many attacks were not immediately treated, the 
physicians were probably able to establish their severity and 
treat them accordingly. Thirdly, we used only EDSS to score 
variations during attacks. This had the limit of lower respon-
siveness than other scales or impossibility to detect cognitive 
symptoms, but assured good agreement between the attack 
evaluators and practicability [1]. Fourthly, one third of our 
attacks were anamnestic. Although every effort was made to 
collect as much information as possible, we cannot entirely 
rule out a bias due to the diversity of data collection. How-
ever, inclusion of both anamnestic and observed attacks al-
lowed examination of a consecutive series of events, and 
separate analysis of anamnestic and observed attacks identi-
fied the same predictors of severity and duration in both 
groups. Fifthly, since our study is hospital-based, a selection 
bias towards more severe cases cannot be excluded; how-
Table 3.  Probability of a Second Moderate/Severe or Long Attack: Multivariate Analysis (N=95) 
  Second moderate/severe attack   Second long attack 
Predictor  HR (95% CI)  p-value   HR (95% CI)  p-value 
Bi-polysimptomatic attack (>1 FS)   2.50 (0.58-10.85)  0.22  2.68 (0.40-17.91)  0.31 
First attack severity (severe vs. others)   1.07 (0.23-4.97)  0.93  0.41 (0.08-1.93)  0.26 
First attack duration (long vs. others)   3.05 (0.87-10.63)  0.08  1.55 (0.44-5.46)  0.50 
Pyramidal FS   0.96 (0.24-3.85)   0.95  1.14 (0.18-7.03)  0.89 
Cerebellar FS   0.95 (0.23-3.93)  0.94  0.90 (0.20-4.13)  0.89 
Brainstem FS  1.22 (0.26-5.66)  0.80  0.34 (0.05-2.20)  0.26 
Sensory FS    1.52 (0.44-5.25)  0.51  0.54 (0.13-2.20)  0.39 
Visual FS   0.35 (0.07-1.69)   0.19  1.12 (0.22-5.67)  0.88 
Age at onset of the attack >30 years  0.79 (0.25-2.43)  0.68  1.01 (0.26-3.86)  0.99 
Attack therapy   0.43 (0.13-1.41)  0.16  0.37 (0.10-1.37)  0.14 
Infection in the preceding month   0.47 (0.10-2.23)  0.34  1.09 (0.21-5.57)  0.92 
Season (autumn/winter vs. spring/summer)    1.38 (0.48-3.94)  0.55  0.56 (0.18-1.78)  0.33 
Male gender   1.75 (0.55-5.56)  0.35  0.82 (0.25-2.65)  0.74 
Incomplete recovery  0.07 (0.02-0.32)   <0.001  0.50 (0.13-1.89)  0.31 82     The Open Neurology Journal, 2011, Volume 5  Naldi et al. 
ever, most MS patients from our catchment areas are seen 
soon after the onset of symptoms and rarely refer to other 
hospitals for an initial assessment. 
In conclusion, our data give support to the idea that each 
attack has its own severity and duration dependent on some 
attack-related predictive factors, but independent on individ-
ual-related predictors or of what happened in previous at-
tacks [1]. Severity displays an intriguing relation with recov-
ery in many studies [1, 2, 4]. However, if a severe attack 
(greater inflammation) is a risk factor for an incomplete re-
covery (failed remyelination), the reverse process has no 
evident foundation, since repairing difficulties in one loca-
tion are not necessarily associated with subsequent greater 
inflammation in the same or other locations. However, we 
did not consider other variables that may serve to predict 
attack characteristics, such as the genetic background, for 
example HLA. An analysis of genetic predictors is war-
ranted. 
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